产品介绍 引用文献(0) 评论(0)
宿主来源
Rabbit抗原名称
sFlt-1分子别名
Soluble Fms-Like Tyrosine Kinase-1, sVEGFR-1免疫原
Recombinant ProteinAccession
P17948克隆号
SDT-233-26抗体类型
Recombinant mAb应用
Sandwich ELISA, CLIA反应种属 ?
Hu交叉反应
Does not recognize PlGF纯化方式
Protein A浓度
2 mg/ml纯度
>95% by HPLC标记
Unconjugated性状
Liquid缓冲体系
PBS pH7.4, 0.03% Proclin 300储存条件
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用 | 稀释度 |
---|---|
Sandwich ELISA | N/A |
Soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) is a tyrosine kinase protein with antiangiogenic properties. A non-membrane associated splice variant of VEGF receptor 1 (Flt-1), sFlt-1 binds the angiogenic factors VEGF (vascular endothelial growth factor) and PlGF (placental growth factor), reducing blood vessel growth through reduction of free VEGF and PlGF concentrations. In humans, sFlt-1 is important in the regulation of blood vessel formation in diverse tissues, including the kidneys, cornea, and uterus. Abnormally high levels of sFlt-1 have been implicated in the pathogenesis of preeclampsia. Preeclampsia (PE) is a hypertensive pregnancy disorder that occurs in approximately 2% to 4% of all pregnancies and is accompanied by substantial morbidity and mortality for both mother and infant and long-term risks for chronic diseases. The exact causes of PE are still unclear, but contributors are systemic endothelial dysfunction, impaired angiogenesis, and decreased vascular compliance. In recent years, research has focused primarily on soluble anti-angiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and pro-angiogenic factors, such as placental growth factor (PlGF). An anti-angiogenic imbalance upon increased sFlt-1 levels has been shown to be a critical factor in the pathogenesis of placentally associated disorders such as PE and is strongly associated with the crucial process of remodelling of the maternal spiral arteries. As an anti-angiogenic factor on the surface of vascular endothelial cells, sFlt-1 blocks the responses of the pro-angiogenic factors vascular endothelial growth factor (VEGF) and PlGF. Those changes in the concentration of angiogenic factors can be measured in maternal blood samples–an elevated sFlt-1/PlGF ratio can occur weeks before clinical symptoms of PE arise. Therefore, measurement of the sFlt-1/PlGF ratio has become an established marker in clinical practice for early prediction of PE.
验证数据
引用文献(0)
评论(0)